Jarvinen et al., 1998 - Google Patents
Induction of protective immunity in rabbits by coadministration of inactivated Pasteurella multocida toxin and potassium thiocyanate extractJarvinen et al., 1998
View PDF- Document ID
- 17325248156201214091
- Author
- Jarvinen L
- Hogenesch H
- Suckow M
- Bowersock T
- Publication year
- Publication venue
- Infection and immunity
External Links
Snippet
Pasteurella multocida is a bacterial pathogen that causes rhinitis (snuffles), pneumonia, otitis media, septicemia, metritis, and death in domestic rabbits. Currently, there are no effective vaccines to prevent infection by this organism. Subcutaneous (sc) immunization …
- 241000283973 Oryctolagus cuniculus 0 title abstract description 110
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9962434B2 (en) | Compositions and methods for treatment of microbial infections | |
| Jacobs et al. | Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi | |
| Lynch et al. | Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12 | |
| EP0786518B1 (en) | Streptococcus equi vaccine | |
| Hoover et al. | Protection of mice against brucellosis by vaccination with Brucella melitensis WR201 (16MΔ purEK) | |
| Amemiya et al. | Nonviable Burkholderia mallei induces a mixed Th1-and Th2-like cytokine response in BALB/c mice | |
| JP2004536106A (en) | Mycoplasma bovis vaccine and method for reducing pneumonia in animals | |
| Bhattacharjee et al. | Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine | |
| Subramaniam et al. | A multivalent Mannheimia-Bibersteinia vaccine protects bighorn sheep against Mannheimia haemolytica challenge | |
| Chandran et al. | Development of a recombinant epsilon toxoid vaccine against enterotoxemia and its use as a combination vaccine with live attenuated sheep pox virus against enterotoxemia and sheep pox | |
| Frandoloso et al. | Development and characterization of protective Haemophilus parasuis subunit vaccines based on native proteins with affinity to porcine transferrin and comparison with other subunit and commercial vaccines | |
| EP1066376B1 (en) | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines | |
| Jarvinen et al. | Induction of protective immunity in rabbits by coadministration of inactivated Pasteurella multocida toxin and potassium thiocyanate extract | |
| Muenthaisong et al. | An intranasal vaccination with a recombinant outer membrane protein H against haemorrhagic septicemia in swamp buffaloes | |
| Shimoji et al. | Construction and vaccine potential of acapsular mutants of Erysipelothrix rhusiopathiae: use of excision of Tn 916 to inactivate a target gene | |
| Nagy et al. | Oral immunization with an rfaH mutant elicits protection against salmonellosis in mice | |
| Hu et al. | A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against Staphylococcus aureus infection | |
| Sukumar et al. | Active and passive immunizations with Bordetella colonization factor A protect mice against respiratory challenge with Bordetella bronchiseptica | |
| Faruque et al. | Diminished diarrheal response to Vibrio cholerae strains carrying the replicative form of the CTXΦ genome instead of CTXΦ lysogens in adult rabbits | |
| Suckow et al. | Field trial of a Pasteurella multocida extract vaccine in rabbits | |
| US6303130B1 (en) | Pasteurella haemolytica vaccine inactivated by ultraviolet light | |
| Kasten et al. | Lack of protection against avian cholera by vaccination with recombinant P6-like protein from Pasteurella multocida | |
| JP2023517684A (en) | Vaccine for protection against Streptococcus suis serotype 9, sequence type 16 | |
| Jarvinen et al. | Intranasal Vaccination of New Zealand White Rabbits Against Pasteurellosis, Using AlginateEncapsulated Pasteurella multocida Toxin and Potassium Thiocyanate Extract | |
| JP2024528172A (en) | Vaccine for protection against various serotypes of Streptococcus suis |